SCHEDULE: FMR LLC Reports Stake in Day One Biopharmaceuticals

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 23,639.69 shares of Day One Biopharmaceuticals common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of Day One Biopharmaceuticals Inc. common stock.
• As of March 31, 2026, the total number of shares beneficially owned by FMR LLC and Abigail P. Johnson is 23,639.69.
• This ownership represents 0.0% of the class of securities.
• FMR LLC is classified as a holding company, while Abigail P. Johnson is an individual investor.
• The filing confirms that no single other person holds more than five percent of the outstanding common stock.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of a minor ownership stake without any significant operational or financial updates from the company itself.

Positives

• FMR LLC and Abigail P. Johnson have disclosed their holdings, providing transparency to the market.
• The filing indicates that the ownership is in the ordinary course of business, suggesting no intent to disrupt or control the company.

Negatives

• The reported ownership stake of 0.0% is negligible in terms of influencing company control or strategy.

Risks

• The filing does not explicitly mention any risks or challenges faced by Day One Biopharmaceuticals Inc.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Day One Biopharmaceuticals Inc.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson is a routine disclosure for significant institutional investors and individuals. It provides transparency regarding ownership stakes in publicly traded companies like Day One Biopharmaceuticals, which operates in the biopharmaceutical sector, an industry characterized by significant research and development investment and regulatory oversight.

Stakeholder Impact

• Shareholders: Provides transparency on ownership structure, though the reported stake is not significant enough to imply control.
• Management: The filing confirms that the reporting persons do not intend to influence control.
• Regulators: Fulfills SEC disclosure requirements.

Next Steps

• Continued monitoring of Day One Biopharmaceuticals Inc. for future SEC filings and operational updates.

Key Dates

Keywords

Schedule 13G, FMR LLC, Abigail P. Johnson, Day One Biopharmaceuticals, Beneficial Ownership, SEC Filing, Common Stock, Investment